Latest Market Capitalisation News

Charger Metals has expanded its Medcalf lithium resource to 10.6 million tonnes at 1.0% Li2O, backed by strong metallurgical results and a fresh $3.75 million cash injection from selling its Bynoe project.

Ragusa Minerals has secured a controlling stake in Pegasus Tel Inc., gaining the Purple Pansy manganese-gold project in Arizona. Recent surveys and assays highlight promising high-grade manganese and gold mineralisation, positioning the company in a strategically important US critical minerals sector.

BLS Pharmaceuticals capped FY2026 with record quarterly revenue and operating cash flow, driven by international expansion and new supply agreements across regulated markets.

American West Metals is progressing its Storm Copper Project towards near-term production while expanding critical metals resources at West Desert, supported by a US$40 million financing and offtake deal.

Vault Minerals delivered on FY26 gold production guidance with strong quarterly output and cash flow, while progressing key projects and announcing a merger with Genesis Minerals to form a top 20 global gold producer.

FireFly Metals has delivered exceptional high-grade copper-gold drilling results from its Green Bay project, prompting an updated resource estimate and pushing its economic study completion to August 2026. The company also simplified its portfolio by selling Ontario gold assets and gained entry into the S&P/ASX 200 Index.

Exultant Mining has kicked off its first drilling campaign at the Balerion Prospect in NSW, intersecting promising sulphide mineralisation while expanding tenure at Black Hammer with the Swatchfield licence grant.

Noronex Ltd has secured a major foothold in the US critical minerals sector by acquiring the Sleitat Tin-Tungsten-Silver Project in Alaska, featuring a substantial historic tin estimate and promising exploration upside.

Critical Resources (ASX:CRR) spotlighted its multi-commodity pipeline and breakthrough battery cooling technology at the July 2026 TechKnow Invest Roadshow, highlighting exploration progress and exclusive global licensing deals.

Patrys Limited is pushing forward with a proprietary injectable formulation of quetiapine targeting the lucrative delirium treatment market, leveraging a faster, lower-cost FDA 505(b)(2) regulatory pathway and strong patent protection.

Monvia Limited, an Australian SaaS provider for life insurers, is seeking to raise $17.5 million via an IPO on the ASX. The funds will support redemption of preference shares and fuel growth in existing and new markets.

Spenda Limited anticipates a significant R&D tax offset exceeding AUD 1.75 million for FY26, providing a timely cash boost amid its push towards cash-flow neutrality.